#USA #Boston #Glytec #KLAS #Glucommander

Glytec Glucommander® Receives KLAS Recognition

Glytec, a leader in AI-powered diabetes and glycemic management technology, has recently received recognition from KLAS for its flagship product, Glucommander®. This advanced platform, which integrates directly with electronic health records (EHR), aims to enhance inpatient diabetes management by improving the accuracy of insulin dosing and minimizing hypoglycemic events in hospital settings.

KLAS Report Overview

The KLAS First Look report highlights a significant achievement among hospitals utilizing Glucommander®. According to the report, facilities that deployed this innovative solution reported a notable decrease in hypoglycemic incidents. While data on hyperglycemic events remains to be finalized, the feedback surrounding insulin dosing accuracy is overwhelmingly positive. This development suggests that Glucommander® is effective in streamlining the glycemic management process and enhancing overall patient safety.

Performance Metrics

Respondents to the KLAS survey rated Glytec highly in various categories, including:

• - Executive involvement and implementation quality: A
• - Vendor partnership: A–
• - Product functionality: B–*

An impressive 93% of users stated they would opt to purchase Glucommander® again, reflecting a strong level of satisfaction and trust in Glytec's capabilities. Patrick Cua, CEO of Glytec, expressed his honor in KLAS recognizing their efforts through real-life improvements in patient safety and standardized protocols for glycemic care.

Key Features of Glucommander®

The KLAS report also underscores Glucommander®'s seamless EHR integration which is validated by major platforms like Epic, Oracle Health, and MEDITECH. This integration significantly enhances nursing workflows, ensuring greater accuracy in documentation and effective insulin management for both intravenous (IV) and subcutaneous (SubQ) insulin administration. Users have reported three key strengths:

• - Ease of use
• - Improved clinical outcomes
• - Responsive vendor support

Glytec's Glucommander® stands out as the first-ever FDA-approved cloud-based insulin management software. It provides hospitals with advanced clinical decision support tools, workflow alerts, thorough patient monitoring, and comprehensive analytics to facilitate effective diabetes management, ultimately leading to improved patient outcomes.

Commitment to Innovation

Glytec’s technology is trusted by over 400 hospitals, playing a pivotal role in transforming diabetes management from the hospital environment to home care. Their platform not only aims to improve clinical workflows but is also focused on reducing hospital stays and readmissions by delivering measurable results. The company boasts over 100 patents and more than 100 peer-reviewed publications, a testament to its commitment to innovation in the healthcare sector.

Access to the Full Report

Healthcare professionals seeking to delve deeper into the insights from the KLAS First Look report can access the document through Glytec's official channels. This recognition not only affirms Glytec's dedication to enhancing diabetes management solutions but also ensures the provision of high-quality care for patients suffering from this chronic condition.

For further information about Glytec and its offerings, visit Glytec's official website or follow the company on LinkedIn to stay updated on their latest advancements and initiatives in diabetes management.

• ---

In an era where healthcare technology continues to evolve rapidly, Glytec's recognition by KLAS marks a significant milestone in the journey of improving inpatient care and represents the potential future of diabetes management.